Perioperative conditions affect long-term hypertrophic scar formation

Area of Science:

• Wound Healing
• Dermatology
• Surgical Outcomes

Background:

• Corticosteroids are used for scar treatment with variable success.
• Systemic corticosteroids may offer broader anti-inflammatory effects for scar prevention.
• Hypertrophic scar formation is a common complication after cardiothoracic surgery.

Purpose of the Study:

• To investigate the efficacy of perioperative systemic dexamethasone in preventing hypertrophic scars.
• To evaluate the impact of dexamethasone on scar dimensions following median sternotomy.

Main Methods:

• A prospective study involving 43 patients undergoing cardiothoracic surgery.
• Administration of high-dose dexamethasone (1 mg/kg preoperatively, 0.5 mg/kg postoperatively) during cardiopulmonary bypass.
• Standardized scar measurements (height, width) using calipers and ultrasound at multiple time points up to 52 weeks.

Main Results:

• No statistically significant difference in the incidence of hypertrophic scars between the dexamethasone and control groups.
• Scars in the dexamethasone group showed significantly increased width (cranial) and height (cranial and caudal) at 12 weeks.
• Negative effects on scar dimensions were more pronounced in patients who developed hypertrophic scars.

Conclusions:

• High-dose perioperative dexamethasone does not prevent hypertrophic scar formation after median sternotomy.
• Perioperative dexamethasone, particularly with cardiopulmonary bypass, can negatively affect scar dimensions.
• Perioperative immunologic responses may play a role in the etiology of hypertrophic scar formation.